Answers are grounded in this paper and cite their sources.
Purpose: The optimal management of Bacillus Calmette-Guérin (BCG)-unresponsive nonmuscle-invasive bladder cancer (NMIBC) remains unclear. This study evaluated the safety and tolerability of a novel intense immunotherapy dosing regimen of avelumab for patients with BCG-unresponsive NMIBC during BCG induction. Materials and Methods: This phase 1b trial, with a 3 + 3 dose escalation design, included 18 patients with a histologically or cytologically documented NMIBC that was unresponsive to BCG treatment. Patients received weekly avelumab (10 mg/kg, intravenous) during BCG (50 mg, intravesical) induction followed by maintenance avelumab and BCG for up to 1 year of treatment (maintenance phase). The primary end point was completion of a full induction course (at least 5 of 6 treatments of BCG + avelumab within 8 weeks of treatment initiation). The secondary end point was completion of 6 months of maintenance treatment. Results: Eighteen patients were enrolled; 15 of 18 (83%) patients completed 5 of 6 courses of planned induction treatment. At the 3-month cystoscopy, 13 of 15 (87%) patients remained on treatment, 10 without evidence of cancer and 3 with persistent disease (2 carcinoma in situ, 1 Ta). No drug-attributable grade 4 or 5 adverse events (AEs) were observed. All patients who discontinued treatment were included in the safety analysis. During induction therapy, 2 (11%) patients had probable drug-related grade 3 AEs, including infusion-related reaction (avelumab) and sepsis (BCG). Conclusions: The combination of BCG and avelumab was safe and well tolerated among patients with BCG-unresponsive NMIBC. This study supports continued efforts to evaluate the optimal dosing regimen to synergize BCG and immunotherapy.
No takes yet. Share an insight, caveat, or question.
Cookson et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: